Explore all the latest information in myeloproliferative neoplasms
, arranged by key congresses and meetings. Listed below are recently updated congresses and meetings.
How should genomic assessment in MF be performed?
Interview with Raajit K. Rampal during SOHO 2020 about how genomic assessment should be performed in patients with myelofibrosis.
How can outcome after transplant be improved for patients with MPN?
Interview with Uday R. Popat, MD Anderson Cancer Center, Houston, US on how to improve outcomes after transplant for patients with...
What is the news about ropeginterferon?
During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to our Steering Committee Chair, Jean-Jacques Kiladjian, Université de Paris, Paris, FR,...
What is the clinical value and potential of momelotinib for anemic patients with myelofibrosis?
During the First Annual Texas Virtual MPN Workshop, the MPN Hub spoke to Abdulraheem Yacoub, University...
Ruxolitinib discontinuation syndrome in patients with myelofibrosis
Ruxolitinib is a Janus kinase (JAK) 1/2 inhibitor that is licensed for the treatment of patients with myelofibrosis (MF) and is...
Targeting CD123 with tagraxofusp in patients with poor prognosis following a JAKi treatment | Recent results from a phase I/II trial
Relapse or treatment failure following treatment with a Janus...
Promising preclinical data on selective HDAC11 inhibition and MPN improvement
During the 61st American Society of Hematology (ASH) Annual Meeting & Exposition (2019), Vasundhara Sharma presented...
Final phase II results of the SMAC mimetic LCL161 for intermediate/high-risk myelofibrosis
The efficacy and safety of the LCL161 was assessed in patients with relapsed or refractory MF of...
American Association of Cancer Research
American Society of Clinical Oncology
American Society of Hematology
European Hematology Association
Society of Hematologic Oncology
Texas MPN Workshop